Understanding the True Costs of ADHD: An Examination of the Whole-Life ImpactPremiere Date: Wednesday, May 25, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, May 25, 2023
|Ann Childress, MD (Moderator)
President, Center for Psychiatry and Behavioral Medicine, Inc.
Associate Professor Child/Adolescent Psychiatry
Touro University Nevada College of Osteopathic Medicine
Clinical Associate Professor
University of Nevada, Las Vegas School of Medicine
Las Vegas, NV
|Thomas E. Brown, PhD
Brown Clinic for Attention & Related Disorders
Manhattan Beach, CA
Clinical Professor of Psychiatry and Neuroscience
University of California, Riverside School of Medicine
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that can persist into adulthood, with a course that impacts brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities. Subsequently, ADHD is associated with an increased risk of morbidity and mortality. It is imperative to acknowledge the whole-being impact of ADHD as well as the variable consequences of this disorder as the individual transitions from childhood to adulthood. This increased awareness should not only facilitate a better understanding of the seriousness of the condition but also provide an impetus to seek and implement treatment.
The first installment of this 4-part CME Outfitters series on ADHD will feature a discussion by Drs. Ann Childress and Thomas E. Brown on the extensive burden and impact of ADHD in children and adults. Additionally, the activity will include the use of a 3-D model highlighting the various systems and domains impacted.
At the end of this CE activity, participants should be able to:
- Identify the extensive burden imposed by ADHD, including brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry, primary care, and/or pediatrics
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports the following financial relationships:
Consultant: : Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals
Research Support: : Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Speakers Bureau: Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Other Financial or Material Support: Writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Brown reports the following financial relationships:
Other Financial or Material Support: Royalties for publications from American Psychiatric Publishing; Jossey-Bass/John Wiley; Routledge; and Yale University Press
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).